How Serum Biomarkers can Guide aGHVD Therapy: Results not matching up with GVHD, TMA (Thrombotic Microangiopathy) and COD

  • Exploration of thrombotic microangiopathy (TMA) and its relationship to aGVHD.
  • Causes of complications of disease (COD) in transplant patients.
  • Key serum biomarkers used in monitoring aGVHD.
  • How biomarkers can indicate disease severity and treatment response.
  • Limitations of relying solely on clinical symptoms versus biomarker results.
  • Factors contributing to mismatches between biomarkers and clinical symptoms.

Length of Presentation: 23 minutes (Part 4 of 4)

Presented by: 

  • Dr. James Ferrara, MD
    Ward-Coleman Chair in Cancer Medicine
    Professor of Pediatrics & Medicine
    Icahn School of Medicine at Mount Sinai

 

Thrombotic MicroAngiopathies (TMA)

TA TMA Icon 2023
TA-TMA

Chat With An Expert

Back to top